XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Note P - Concentration | 12 Months Ended
--- | ---
Dec. 31, 2017
Notes to Financial Statements |
Concentration Risk Disclosure [Text Block] | NOTE P -- CONCENTRATION Milestone Scientific has informal arrangements with a third -party manufacturer of the STA, CompuDent® and CompuMed® instruments, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. In March 2016, Milestone Scientific entered into a purchase commitment for delivery of 3,000 instruments, as of December 31, 2017 all instruments have been received. In January 2017 Milestone Scientific entered into a purchase commitment for the delivery of 2,000 instruments beginning in the 4th quarter of 2017. An advance of $697,192 was recorded at December 31, 2017. At December 31, 2017, Milestone Scientific’s purchase commitment for this purchase order was $300,460. An advance of $656,752 was recorded at December 31, 2016. At December 31, 2016, Milestone Scientific’s purchase commitment for this purchase order was $272,231. Consequently, advances on contracts have been classified as current at December 31, 2017 and 2016 respectively. For twelve months ended December 31, 2017, an aggregate of approximately 70% of Milestone Scientific's net product sales were to two customers/ distributors ( one of which, Milestone China, is a related party), 51% and 19%, respectively. For twelve months ended December 31, 2016, an aggregate of approximately 58% of Milestone Scientific's net product sales were to two customers/distributors ( one of which, Milestone China, is a related party), 31%, and 27%, respectively. Accounts receivable for the major customer/distributors amounted to an aggregate of approximately $2,555,476, or 78% of Milestone Scientific's accounts receivable for twelve months ended December 31, 2017. Accounts receivable for the major customer/distributors amounted to an aggregate of approximately $2,994,686, or 85% of Milestone Scientific's accounts receivable for twelve months ended December 31, 2016.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration